Personalized Medicine Debate - Pharmacogenetics
15-10-2019 15:00 15-10-2019 17:00 Aurora Vrije Universiteit

When: Tuesday 15th of October 2019, 15:00-17:00.

Where: AURORA, VU

On behalf of the program leaders of de APH program Personalized Medicine we would like to invite you to the first event in the Personalized Medicine Debate Series:

Pharmacogenetics; reality or dream?

Time for a debate with experts:

Confirmed speakers are:

Clinical Pharmacologist Pierre Bet (Amsterdam UMC, location VUmc)

Prof. Martina Cornel (Amsterdam UMC, location VUmc)

Prof. Henk van Weert (Amsterdam UMC, location AMC)

Consultant HTA and health economics Anke Hövels (UMCU)

Moderator:

Meike Bartels/ Dick Willems

Please click here to register and stay updated.

-------------------------------------------------------------------------------------------------------------------------------------

Background:

In September 2017 the national guideline for colorectal carcinoma was updated to recommend DPD genotyping before treatment with fluoropyrimidines. This is an example of personalized medicine as a result of the developments in the field of Pharmacogenetics.

Effective implementation of pharmacogenetic guidelines, clinical utility of genotyping vs phenotyping at the enzyme level, the cost-effectiveness of such approaches, and the innovative application of a pre-emptive pharmacogenomics panel are subjects of study within the APH-Personalized Medicine program.

With this debate, we hope to evaluate and stimulate responsible implementation of pharmacogenomics, as well as other personalized medicine approaches, in light of our proposed value-based healthcare framework. We hope to discuss the relevance of (transparency about) the different values at stake when evaluating personalised medicine application.(see white paper)

Propositions:

-          Clinical utility of available tests should be the main criterion for implementation

-          Clinicians have a responsibility to weigh the allocative value of the available interventions for their patients

-          Patients should have the right to have access to their pharmacogenetic data, if whole exome sequencing is performed

-          Avoiding harm (side-effects) is a more appropriate aim for pharmacogenomics than beneficence (predicting desired effects)

Program:

14:45 – 15:00 Opening with coffee and tea

15:00 - 15:20: General Introduction – Pierre Bet

15:20 – 15:30: Martine Cornel - DPD testing before treatment

15.30 - 16.00: Response from debaters (Henk van Weert, Anke Hövels, Martina Cornel, NPCF)

16:00 - 16:40: Propositions

16:40 - 16:45: Closure

16:45 - 17:30: Drinks

Please click here to register and stay updated: https://forms.gle/NGWCE76KvMPud7Sw9

(Circa 50 seats available!)